EFO-27 Cells
USD$430.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The EFO-27 cell line is a human ovarian carcinoma model derived from a moderately differentiated serous papillary adenocarcinoma. It was established from a solid omental metastasis in a patient with advanced-stage ovarian cancer. EFO-27 is part of a series of ovarian tumor-derived cell lines developed to explore the hormonal regulation of ovarian cancer cell proliferation. In early passages, EFO-27 was reported to be aneuploid, with a modal chromosome number exceeding 100, indicating a high degree of chromosomal instability, a common feature of high-grade serous ovarian carcinomas. EFO-27 cells display an epithelioid morphology in vitro and have been shown to form dome-like multicellular structures in monolayer culture, a phenotype sometimes associated with active ion transport and tight junction formation. In serum-free media, the proliferation of EFO-27 was stimulated by gonadotropic hormones, specifically human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH), suggesting that the cells retain functional hormone receptor signaling pathways. This responsiveness highlights the potential role of gonadotropin signaling in promoting tumor growth and progression in ovarian carcinoma and supports EFO-27 as a relevant model for studying hormone-driven mechanisms in ovarian cancer biology. EFO-27 has also been included in major multi-omics datasets, such as the Cancer Cell Line Encyclopedia (CCLE) and COSMIC, where its genomic profile contributes to drug sensitivity mapping and tumor subtype classification. These datasets provide additional layers of information, including gene expression, copy number alterations, and mutational landscape, positioning EFO-27 as a well-characterized resource for preclinical research in ovarian cancer. |
|---|---|
| Organism | Human |
| Tissue | Metastatic |
| Disease | Ovarian mucinous adenocarcinoma |
| Metastatic site | Omentum |
| Synonyms | EFO 27, EFO27 |
Characteristics
| Age | 36 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Cell type | Epithelioid cells growing adherently as monolayer |
| Growth properties | Adherent |
Regulatory Data
| Citation | EFO-27 (Cytion catalog number 305769) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1192 |
Biomolecular Data
| Mutational profile | Mutation: PTEN, Simple, p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA), Heterozygous (Cosmic-CLP=906852), TP53, Simple, p.Arg273Cys (c.817C>T), Heterozygous (Cosmic-CLP=906852) |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% FBS, additional 2.0 mM L-Glutamine, 1% NEAA, 1 mM sodium pyruvate |
| Dissociation Reagent | Accutase |
| Doubling time | 29 hours |
| Seeding density | 1 to 3 x 104 cells/cm2 |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305769-070426 | Certificate of Analysis | 15. May. 2026 | 305769 |